Corvus Pharmaceuticals (CRVS) Cash from Operations (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Cash from Operations came in at 10374000.0 in Q1 2026, down 25.55% year-on-year from 13933738.95 in Q1 2025, and down 12.87% quarter-over-quarter from 9191000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Cash from Operations (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 10374000.0 for Q1 2026.
- On a quarterly basis, Cash from Operations fell 25.55% year-over-year to 10374000.0 in Q1 2026; TTM through Mar 2026 was 34908000.0, a 22.36% decrease from a year earlier, with the FY2025 full-year figure at 32797000.0, down 29.0% from the prior year.
- Cash from Operations retreated to 10374000.0 in Q1 2026 per CRVS's latest filing, from 9191000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5157000.0 in Q1 2024 and bottomed at 10374000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 6424000.0 (2022), against an average of 7032529.41.
- Across the five-year window, Cash from Operations surged 51.59% in 2022 and sank 63.83% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 7547000.0 in 2022, then surged by 31.54% to 5167000.0 in 2023, then slumped by 63.83% to 8465000.0 in 2024, then retreated by 8.58% to 9191000.0 in 2025, then fell by 12.87% to 10374000.0 in 2026.
- Per Business Quant, the three latest CRVS Cash from Operations figures stand at 10374000.0 (Q1 2026), 9191000.0 (Q4 2025), and 9566000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.37 Mn |
| Mar 31, 2026 | -10.37 Mn |
| Dec 31, 2025 | -9.19 Mn |
| Dec 31, 2025 | -9.19 Mn |
| Sep 30, 2025 | -9.57 Mn |
| Sep 30, 2025 | -9.57 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Mar 31, 2025 | -8.26 Mn |
| Mar 31, 2025 | -8.26 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Sep 30, 2024 | -6.32 Mn |
| Sep 30, 2024 | -6.32 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -5.16 Mn |
| Mar 31, 2024 | -5.16 Mn |
| Dec 31, 2023 | -5.17 Mn |
| Dec 31, 2023 | -5.17 Mn |